Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 11/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL905742 | 0.84 | ALDH1A1 (0.49) | MTNR1AMTNR1BKDM4EALDH1A1MAPT | |
| SCHEMBL905702 | 0.82 | MTNR1A (0.43) | MTNR1AMTNR1BALDH1A1ELANE | |
| SCHEMBL31596506 | 0.82 | MTNR1A (0.50) | MTNR1AMTNR1BKDM4EALDH1A1MAPT | |
| SCHEMBL27595069 | 0.79 | MTNR1A (0.42) | MTNR1AMTNR1BGLAKDM4EALDH1A1 | |
| SCHEMBL3573582 | 0.78 | MTNR1A (0.47) | MTNR1AMTNR1BKDM4EALDH1A1TSHR | |
| SCHEMBL29685513 | 0.78 | MTNR1A (0.47) | MTNR1AMTNR1BKDM4EALDH1A1TSHR | |
| SCHEMBL28853339 | 0.72 | MTNR1A (0.40) | MTNR1AMTNR1BKDM4EALDH1A1MAPT | |
| SCHEMBL27698463 | 0.71 | ALDH1A1 (0.43) | MTNR1AMTNR1BKDM4EALDH1A1MAPT | |
| SCHEMBL854498 | 0.71 | PARP1 (0.50) | PARP1GLAADORA2AALDH1A1 | |
| SCHEMBL1172748 | 0.71 | ELANE (0.39) | MTNR1AMTNR1BGLAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101160307-A | Benzoxazole carboxamides for the treatment of CINV and IBS-D | AMR TECHNOLOGY INC (US) | 2008-04-09 | — | — | CN | claimed |
| CN-115124485-B | Sulfoxide-containing benzoxazole derivative, and preparation method and application thereof | 中国医学科学院药物研究所 | 2023-12-15 | — | — | CN | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| CN-115124485-A | Benzoxazole derivatives containing sulfoxide as well as preparation method and application thereof | 中国医学科学院药物研究所 | 2022-09-30 | — | — | CN | disclosed |
| EP-3843853-A1 | HETEROCYCLIC COMPOUNDS AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020043880-A1 | HETEROCYCLIC COMPOUNDS AS AHR MODULATORS | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2020-03-05 | — | — | WO | disclosed |
| WO-2016100161-A1 | ETHYLDIAMINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2016-06-23 | — | — | WO | disclosed |
| CN-101160307-A | Benzoxazole carboxamides for the treatment of CINV and IBS-D | AMR TECHNOLOGY INC (US) | 2008-04-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | MTNR1A 4131/4885MTNR1B 2395/4885PARP1 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.